Post-Traumatic Stress Disorder Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscience, Jazz

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Post-Traumatic Stress Disorder pipeline constitutes 25+ key companies continuously working towards developing 25+ Post-Traumatic Stress Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Post-Traumatic Stress Disorder Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Post-Traumatic Stress Disorder Market.

The Post-Traumatic Stress Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Post-Traumatic Stress Disorder Pipeline Report: https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Post-Traumatic Stress Disorder treatment therapies with a considerable amount of success over the years.
• Post-Traumatic Stress Disorder companies working in the treatment market are Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscience, Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceuticals, Nobilis Ther@peutics, Boehringer Ingelheim, Bionorica SE, H. Lundbeck A/S, and others, are developing therapies for the Post-Traumatic Stress Disorder treatment
• Emerging Post-Traumatic Stress Disorder therapies in the different phases of clinical trials are- Lu AG06466, EMP-01, BNC210, ALTO-100, JZP150, NYX-783, Brexpiprazole, NBTX-001, BI 1358894, BX-1, Lu AG06466, and others are expected to have a significant impact on the Post-Traumatic Stress Disorder market in the coming years.
• In October 2022, Osanetant (ACER-801), a medication for treating acute stress disorder and post-traumatic stress disorder (PTSD), has been given a new indication by Acer Ther@peutics Inc.
• In September 2022, EMP-01, a 3,4-methylenedioxy-methamphetamine (MDMA) derivative being developed by atai Life Sciences N.V. for the treatment of post-traumatic stress disorder (PTSD) and other indications, has received the regulatory and ethics approvals needed from Medsafe and HDEC, respectively, to begin enrolling participants in the study's Phase 1.
• In May 2022, A poster containing information from preclinical tests of Aptinyx's NYX-783 in PTSD model organisms was displayed at the American Psychiatric Association Annual Meeting, which took place in New Orleans, Louisiana, from May 21 to 25, 2022.
• In May 2022, A research and development partnership between Beckley Psytech Limited and Lophora ApS was announced. According to the terms of the agreement, Beckley Psytech will work closely with other R&D partners and jointly support the Lophora pipeline's continued development.
• In May 2022, Ananda Scientific Inc. and the University of Nebraska Medical Centre (UNMC) have joined forces for a brand-new clinical trial looking at PTSD treatment for adults. The NantheiaTM ATL5, an investigational medicine that uses cannabidi0l in ANANDA's unique delivery system, will be the subject of the trial to determine its efficacy. The U.S. Food and Drug Administration (FDA) has authorized an investigational new drug (IND) application for the experiment.
• In February 2022, A phase II clinical research sponsored by Alto Neuroscience is being enrolled in by Novamind Inc. The "Alto Clinical Trial" is an eight-week clinical trial being conducted at Novamind's Dr@per, Utah research facility to examine an antidepressant drug for individuals with major depressive disorder (MDD) and post-traumatic stress disorder (PTSD).

Post-Traumatic Stress Disorder Overview
People who have encountered or witnessed a traumatic incident, such as a natural disaster, a catastrophic accident, a terrorist attack, war or conflict, or r@pe, or who have been threatened with death, sexual violence, or serious injury, may develop post-traumatic stress disorder (PTSD), a psychiatric disease.

Get a Free Sample PDF Report to know more about Post-Traumatic Stress Disorder Pipeline Ther@peutic Assessment-
https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Post-Traumatic Stress Disorder Drugs Under Different Phases of Clinical Development Include:
• Lu AG06466: Lundbeck
• EMP-01: Atai Life Sciences
• BNC210: Bionomics Limited
• ALTO-100: Alto Neuroscience
• JZP150: Jazz Pharmaceuticals
• NYX-783: Aptinyx
• Brexpiprazole: Otsuka Pharmaceuticals
• NBTX-001: Nobilis Ther@peutics
• BI 1358894: Boehringer Ingelheim
• BX-1: Bionorica SE
• Lu AG06466: H. Lundbeck A/S

Post-Traumatic Stress Disorder Route of Administration
Post-Traumatic Stress Disorder pipeline report provides the ther@peutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Post-Traumatic Stress Disorder Molecule Type
Post-Traumatic Stress Disorder Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Post-Traumatic Stress Disorder Pipeline Ther@peutics Assessment
• Post-Traumatic Stress Disorder Assessment by Product Type
• Post-Traumatic Stress Disorder By Stage and Product Type
• Post-Traumatic Stress Disorder Assessment by Route of Administration
• Post-Traumatic Stress Disorder By Stage and Route of Administration
• Post-Traumatic Stress Disorder Assessment by Molecule Type
• Post-Traumatic Stress Disorder by Stage and Molecule Type

DelveInsight's Post-Traumatic Stress Disorder Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Post-Traumatic Stress Disorder product details are provided in the report. Download the Post-Traumatic Stress Disorder pipeline report to learn more about the emerging Post-Traumatic Stress Disorder therapies at:
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Post-Traumatic Stress Disorder Ther@peutics Market include:
Key companies developing therapies for Post-Traumatic Stress Disorder are - Aptinyx, Nobilis Ther@peutics Inc., Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, Otsuka Pharmaceutical Development & Commercialization, Inc., Halucenex Life Sciences, Bionorica SE, MAPS Europe B.V., Hoffmann-La Roche, Praxis Precision Medicines, Alto Neuroscience, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Psy Ther@peutics Inc, Chronos Ther@peutics, Mydecine Innovations Group, ATAI LIFE SCIENCES N.V., Acer Ther@peutics, Alzamend Neuro, Inc., Innovation1 Biotech Inc., Lophora, Virpax Pharmaceuticals, Alto Neuroscience, VistaGen, ANANDA Scientific, Bright Minds Biosciences, and others.

Post-Traumatic Stress Disorder Pipeline Analysis:
The Post-Traumatic Stress Disorder pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
• It accesses the Different ther@peutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
• Post-Traumatic Stress Disorder key companies are involved in targeted ther@peutics development with respective active and inactive (dormant or discontinued) projects.
• Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Post-Traumatic Stress Disorder drugs and therapies-
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Post-Traumatic Stress Disorder Pipeline Market Drivers
• Increase in prevalence, increased initiatives to create public awareness and knowledge of disease are some of the important factors that are fueling the Post-Traumatic Stress Disorder Market.

Post-Traumatic Stress Disorder Pipeline Market Barriers
• However, heterogeneity of the symptoms, delayed-onset PTSD and other factors are creating obstacles in the Post-Traumatic Stress Disorder Market growth.

Scope of Post-Traumatic Stress Disorder Pipeline Drug Insight
• Coverage: Global
• Key Post-Traumatic Stress Disorder Companies: Lundbeck, Atai Life Sciences, Bionomics Limited, Alto Neuroscience, Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceuticals, Nobilis Ther@peutics, Boehringer Ingelheim, Bionorica SE, H. Lundbeck A/S, and others
• Key Post-Traumatic Stress Disorder Therapies: Lu AG06466, EMP-01, BNC210, ALTO-100, JZP150, NYX-783, Brexpiprazole, NBTX-001, BI 1358894, BX-1, Lu AG06466, and others
• Post-Traumatic Stress Disorder Ther@peutic Assessment: Post-Traumatic Stress Disorder current marketed and Post-Traumatic Stress Disorder emerging therapies
• Post-Traumatic Stress Disorder Market Dynamics: Post-Traumatic Stress Disorder market drivers and Post-Traumatic Stress Disorder market barriers

Request for Sample PDF Report for Post-Traumatic Stress Disorder Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Post-Traumatic Stress Disorder Report Introduction
2. Post-Traumatic Stress Disorder Executive Summary
3. Post-Traumatic Stress Disorder Overview
4. Post-Traumatic Stress Disorder- Analytical Perspective In-depth Commercial Assessment
5. Post-Traumatic Stress Disorder Pipeline Ther@peutics
6. Post-Traumatic Stress Disorder Late Stage Products (Phase II/III)
7. Post-Traumatic Stress Disorder Mid Stage Products (Phase II)
8. Post-Traumatic Stress Disorder Early Stage Products (Phase I)
9. Post-Traumatic Stress Disorder Preclinical Stage Products
10. Post-Traumatic Stress Disorder Ther@peutics Assessment
11. Post-Traumatic Stress Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Post-Traumatic Stress Disorder Key Companies
14. Post-Traumatic Stress Disorder Key Products
15. Post-Traumatic Stress Disorder Unmet Needs
16 . Post-Traumatic Stress Disorder Market Drivers and Barriers
17. Post-Traumatic Stress Disorder Future Perspectives and Conclusion
18. Post-Traumatic Stress Disorder Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Post-Traumatic Stress Disorder Market https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Post-Traumatic Stress Disorder-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Post-Traumatic Stress Disorder Epidemiology https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Post-Traumatic Stress Disorder Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.